Assume you are representing an American firm in the pharmaceutical industry. You are assigned to develop an alliance with a Japanese pharmaceutical firm to co-produce a heart medicine. This medicine is one that your firm developed, but you want the proposed alliance to result in the manufacturing of the product in Japan.
In the context of organizational strategy and structure, what are the issues you want to discuss with the Japanese firm as you begin your negotiations? What are the concerns you have as you proceed in these negotiations?
